Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.
View/ Open
Date
2019-08ICR Author
Author
Leung, SCY
Nielsen, TO
Zabaglo, LA
Arun, I
Badve, SS
Bane, AL
Bartlett, JMS
Borgquist, S
Chang, MC
Dodson, A
Ehinger, A
Fineberg, S
Focke, CM
Gao, D
Gown, AM
Gutierrez, C
Hugh, JC
Kos, Z
Laenkholm, A-V
Mastropasqua, MG
Moriya, T
Nofech-Mozes, S
Osborne, CK
Penault-Llorca, FM
Piper, T
Sakatani, T
Salgado, R
Starczynski, J
Sugie, T
van der Vegt, B
Viale, G
Hayes, DF
McShane, LM
Dowsett, M
International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG)
Type
Journal Article
Metadata
Show full item recordAbstract
Aims The nuclear proliferation marker Ki67 assayed by immunohistochemistry has multiple potential uses in breast cancer, but an unacceptable level of interlaboratory variability has hampered its clinical utility. The International Ki67 in Breast Cancer Working Group has undertaken a systematic programme to determine whether Ki67 measurement can be analytically validated and standardised among laboratories. This study addresses whether acceptable scoring reproducibility can be achieved on excision whole sections. Methods and results Adjacent sections from 30 primary ER + breast cancers were centrally stained for Ki67 and sections were circulated among 23 pathologists in 12 countries. All pathologists scored Ki67 by two methods: (i) global: four fields of 100 tumour cells each were selected to reflect observed heterogeneity in nuclear staining; (ii) hot-spot: the field with highest apparent Ki67 index was selected and up to 500 cells scored. The intraclass correlation coefficient (ICC) for the global method [confidence interval (CI) = 0.87; 95% CI = 0.799-0.93] marginally met the prespecified success criterion (lower 95% CI ≥ 0.8), while the ICC for the hot-spot method (0.83; 95% CI = 0.74-0.90) did not. Visually, interobserver concordance in location of selected hot-spots varies between cases. The median times for scoring were 9 and 6 min for global and hot-spot methods, respectively. Conclusions The global scoring method demonstrates adequate reproducibility to warrant next steps towards evaluation for technical and clinical validity in appropriate cohorts of cases. The time taken for scoring by either method is practical using counting software we are making publicly available. Establishment of external quality assessment schemes is likely to improve the reproducibility between laboratories further.
Collections
Subject
International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG)
Humans
Breast Neoplasms
Ki-67 Antigen
Observer Variation
Immunohistochemistry
Reproducibility of Results
Pathology, Clinical
Female
Biomarkers, Tumor
Research team
Endocrinology
Language
eng
Date accepted
2019-04-19
License start date
2019-08
Citation
Histopathology, 2019, 75 (2), pp. 225 - 235
Related items
Showing items related by title, author, creator and subject.
-
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Lawrenson, K; Kar, S; McCue, K; Kuchenbaeker, K; Michailidou, K; et al. (NATURE PORTFOLIO, 2016-09-07)A locus at 19p13 is associated with breast cancer (BC) and ovarian cancer (OC) risk. Here we analyse 438 SNPs in this region in 46,451 BC and 15,438 OC cases, 15,252 BRCA1 mutation carriers and 73,444 controls and identify ... -
The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2).
Matz, M; Coleman, MP; Sant, M; Chirlaque, MD; Visser, O; et al. (2017-02)Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this ... -
Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
Nielsen, TO; Leung, SCY; Rimm, DL; Dodson, A; Acs, B; et al. (2020-12-28)Ki67 immunohistochemistry, commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 Working Group (IKWG) consensus ...